Axa S.A. Bio N Tech Se Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

A detailed history of Axa S.A. transactions in Bio N Tech Se stock. As of the latest transaction made, Axa S.A. holds 94,299 shares of BNTX stock, worth $9.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

94,299

Previous 94,273 0.03%

Holding current value

$9.4 Million

Previous $7.58 Million 47.84%

% of portfolio

0.03%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $2,037 - $3,241	26 Added 0.03%	94,299 $11.2 Million
Q2 2024 Aug 14, 2024	SELL	$80.36 - $102.87 $6 Million - $7.69 Million	-74,713 Reduced 44.21%	94,273 $7.58 Million
Q1 2024 May 15, 2024	SELL	$88.96 - $112.35 $879,458 - $1.11 Million	-9,886 Reduced 5.53%	168,986 $15.6 Million
Q4 2023 Jul 16, 2024	BUY	$90.91 - $112.75 $898,736 - $1.11 Million	9,886 Added 5.85%	178,872 $18.9 Million
Q4 2023 Feb 14, 2024	SELL	$90.91 - $112.75 $1.81 Million - $2.24 Million	-19,886 Reduced 10.01%	178,872 $18.9 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $411,434 - $522,459	-4,177 Reduced 2.06%	198,758 $21.6 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $1.94 Million - $2.46 Million	18,940 Added 10.29%	202,935 $21.9 Million
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $14.2 Million - $17.8 Million	115,715 Added 169.47%	183,995 $22.9 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $8.09 Million - $12.7 Million	68,280 New	68,280 $10.3 Million
Q4 2020 Feb 12, 2021	SELL	$72.71 - $129.54 $225,400 - $401,574	-3,100 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$57.81 - $104.17 $179,211 - $322,927	3,100 New	3,100 $215,000

Others Institutions Holding BNTX

# of Institutions

358

Shares Held

38.4M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account